Loading
In 1992 she was the first patient with recurrent HER2-positive breast cancer to be treated with the antibody that became Herceptin, in Dennis Slamon's trial at UCLA. She became its first long-term survivor.
Barbara Bradfield had HER2-positive breast cancer that had recurred and spread when, in 1992, Dennis Slamon at UCLA asked her to join the first clinical trial of the humanised anti-HER2 antibody, later trastuzumab. She initially declined further treatment, then agreed; her disease responded and did not return. Her case, told in Robert Bazell's book Her-2 and dramatised in the 2008 film Living Proof, gave the programme evidence at a moment when its future inside Genentech was uncertain. Trastuzumab was approved by the FDA in 1998 for metastatic HER2-positive disease and, after the adjuvant trials of 2005, for early disease, changing a subtype once regarded as among the worst into one of the more treatable. She remained a public voice for the trial participants whose consent made the drug possible.
Shares Trials enrol too few, too slowly and the tags hero, patient.
Shares Trials enrol too few, too slowly and the tags hero, patient.
Shares Trials enrol too few, too slowly and the tags hero, patient.
Shares Trials enrol too few, too slowly and the tags hero, patient.
Shares the tags hero, patient.
Shares the tags hero, patient.
Shares the tags hero, patient.
Shares the tags hero, patient.